UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

____________________

FORM 8-K
____________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 1429, 2026

MIMEDX GROUP, INC.

(Exact name of registrant as specified in charter)

Florida

001-35887

26-2792552

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

1775 West Oak Commons Ct., NE, Marietta GA 30062

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (770) 651-9100

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange
on which registered

Common Stock, $0.001 par value per share

MDXG

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Item~~Important ~~5.02~~Cautionary ~~Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Statement

OnThis ~~April~~report ~~14,~~includes ~~2026,~~forward-looking ~~MiMedx~~statements. ~~Group,~~Statements ~~Inc.~~regarding: (~~the~~i) ~~“Company”~~future sales or sales growth; (ii) ~~instituted~~our a2026 ~~cost~~and ~~reduction~~longer ~~initiative~~term ~~intended~~financial togoals ~~prioritize~~and ~~growth~~expectations ~~opportunities~~for future financial results, ~~streamline~~including ~~operations~~levels ~~and~~of ~~significantly~~net ~~reduce~~sales, ~~operating~~Adjusted EBITDA, Adjusted EBITDA margin, corporate expenses. Asand ~~part~~cash; of(iii) ~~these~~our ~~changes~~expectations ~~Ricci~~regarding ~~Whitlow’s~~the ~~position~~placental oftissue ~~Chief~~market; ~~Operating~~(iv) ~~Officer~~our ~~was~~expectations ~~eliminated~~regarding Medicare reimbursement; and ~~she~~(v) ~~departed~~performance ~~from~~in ~~the~~different ~~Company~~care ~~immediately.~~settings, Msare forward-looking statements. ~~Whitlow’s~~Additional ~~departure~~forward-looking ~~was~~statements ~~not~~may abe ~~result~~identified ofby awords ~~disagreement~~such ~~with~~as ~~the~~“believe,” ~~Company.~~“expect,” “may,” “plan,” “goal,” “outlook,” “potential,” “will,” “preliminary,” and similar expressions, and are based on management’s current beliefs and expectations.

~~Also~~Forward-looking instatements ~~connection~~are ~~with~~subject to risks and uncertainties, and the Company’s ~~cost~~cautions ~~reduction~~investors ~~initiative,~~against ~~CEO~~placing ~~Joe~~undue ~~Capper’s~~reliance ~~base~~on ~~salary~~such ~~was~~statements. ~~reduced~~Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) future sales are uncertain and are affected by ~~20%~~competition, access to customers, patient access to healthcare providers, the reimbursement environment and many other factors; (ii) the ~~base~~Company ~~salaries~~may ofchange ~~each~~its ofplans due to unforeseen circumstances; (iii) the results of scientific research are uncertain and may have little or no value; (iv) our ability to sell our products in other ~~named~~countries ~~executive~~depends ~~officers,~~on ~~CFO~~a ~~Doug~~number ~~Rice~~of factors including adequate levels of reimbursement, ~~GC/CAO~~market ~~William~~acceptance ~~“Butch”~~of ~~Hulse~~novel therapies, and ~~CCO~~our ~~Kimberly~~ability ~~Maersk-Moller,~~to ~~were~~build ~~reduced~~and bymanage ~~10%~~a direct sales force or third party distribution relationship; (v) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies; and (vi) we may alter the timing and amount of planned expenditures for research and development based regulatory developments. ~~These~~The ~~reductions~~Company ~~are~~describes ~~applicable~~additional ~~through~~risks ~~December~~and ~~31,~~uncertainties ~~2026~~in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this report and the Company assumes no obligation to update any forward-looking statement.

Item 72.0102 ~~Regulation~~Results FDof ~~Disclosure~~Operations and Financial Condition

On April 1629, 2026, MiMedx Group, Inc. (the “Company”), issued a press release (the “Earnings Press Release”) announcing its ~~cost~~results ~~reduction~~for ~~initiative~~the first quarter of 2026. A copy of the ~~press~~Earnings ~~release~~Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The foregoing information inis ~~this~~furnished ~~Current~~pursuant ~~Report~~to Item 2.02, “Results of Operations and Financial Condition”, including Exhibit 99.1 attached hereto, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,. ~~nor~~It ~~shall~~may ~~such~~only ~~information~~ be ~~deemed~~ incorporated by reference ininto ~~any~~another filing under the Exchange Act or Securities Act of 1933, as amended (the “Securities Act”), ~~except~~if such subsequent filing specifically references this Form 8-K. All information in the Earnings Press Release speaks as ~~expressly~~of ~~set~~the ~~forth~~date bythereof ~~specific~~and ~~reference~~the Company does not assume any obligation to update such information in the future. In addition, the Company disclaims any inference regarding the materiality of such ~~filing~~information which otherwise may arise as a result of its furnishing such information under Item 2.02 of this report on Form 8-K.

Item 97.01 ~~Financial~~Regulation ~~Statements and Exhibits~~FD

On April 29, 2026 at 4:30 PM Eastern Daylight Time, the Company intends to host a conference call and webcast (the “Earnings Call”) to discuss its financial and operating results for the first quarter of 2026. A copy of the slide presentation to be used by the Company in connection with the Earnings Call is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

The Company updated its investor presentation on April 29, 2026. A copy of the presentation materials is furnished as Exhibit 99.3 and is incorporated herein by reference.

The foregoing information is furnished pursuant to Item 7.01, including Exhibit 99.2 attached hereto, and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. It may only be incorporated by reference into another filing under the Exchange Act or Securities Act if such subsequent filing specifically references this Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description of Exhibit
99.1						Earnings Press Release dated April 1629, 2026
104						The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
99.2						Earnings Call Presentation dated April 29, 2026
99.3						Investor Presentation dated April 29, 2026
104						The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		MIMEDX GROUP, INC.
April 16, 2026	By:	/s/ Doug Rice
April 29, 2026	By:	/s/ Doug Rice
		Doug RiceChief Financial Officer

Filing Compare · MIMEDX GROUP, INC.